GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high ...

Eli Lilly & Co. on Tuesday will ask the Seventh Circuit to set a standard process for determining when workers can pool ...

Shares in the chipmaker were lower in pre-market trading, after closing Friday’s session with a 3% drop, following the launch ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

External hiring of finance chiefs hit a 10-year high in 2024, according to Crist Kolder Associates' annual report.

Fortune 500 companies are hiring external CFOs at record levels, with 47.1% of appointments in 2024 coming from outside.

Expect to see the pace accelerate at the Eli Lilly and Co. project on Lebanon’s north side as weather warms. The $9 million ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...